C4 Therapeutics (CCCC) Profit After Tax (2019 - 2026)

C4 Therapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$25.5 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 3.12% year-over-year to -$25.5 million in Q1 2026; TTM through Mar 2026 was -$104.1 million, a 1.24% decrease from a year earlier, with the FY2025 full-year figure at -$105.0 million, changed 0.14% from the prior year.
• Profit After Tax eased to -$25.5 million in Q1 2026 per CCCC's latest filing, from -$20.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$17.7 million in Q2 2024 and bottomed at -$37.2 million in Q4 2022.
• The 5-year median for Profit After Tax is -$28.4 million (2024), against an average of -$28.9 million.
• Across the five-year window, Profit After Tax plunged 128.59% in 2022 and surged 50.68% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$37.2 million in 2022, then climbed by 17.38% to -$30.7 million in 2023, then slipped by 13.76% to -$35.0 million in 2024, then surged by 41.43% to -$20.5 million in 2025, then decreased by 24.48% to -$25.5 million in 2026.
• Per Business Quant, the three latest CCCC Profit After Tax figures stand at -$25.5 million (Q1 2026), -$20.5 million (Q4 2025), and -$32.0 million (Q3 2025).